Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Public ClinicalTrials.gov record NCT03500159. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, multi-center, double-blind, parallel-group study, enrolling approximately 100 male subjects diagnosed with CP/CPPS to evaluate the effect of 12-week treatment with AQX-1125 (active drug) compared to placebo. The subjects will be randomized to receive orally once-daily either AQX-1125 (200 mg) or placebo in a 1:1 ratio across approximately 30 centers in North America (United States and Canada). The study will consist of a screening period of up to 3 weeks, a 12-week treatment period followed by a 4-week off drug safety follow-up period, and an ophthalmic safety follow-up call at 3 months and visit at 6 months post last dose, for a total study duration of about 41 weeks.
Study identification
- NCT ID
- NCT03500159
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 3 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2018 (Actual)
- Primary completion
- Jul 17, 2018 (Actual)
- Completion
- Jul 17, 2018 (Actual)
- Last update posted
- Jan 9, 2019
2018
United States locations
- U.S. sites
- 23
- U.S. states
- 17
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 1026 | Homewood | Alabama | 35209 | — |
| Site 1010 | Mobile | Alabama | 36608 | — |
| Site 1004 | Tucson | Arizona | 85710 | — |
| Site 1028 | Laguna Hills | California | 92653 | — |
| Site 1018 | Los Alamitos | California | 90720 | — |
| Site 1016 | Los Angeles | California | 90048 | — |
| Site 1020 | Los Angeles | California | 90048 | — |
| Site 1027 | New Port Richey | Florida | 34653 | — |
| Site 1013 | Coeur d'Alene | Idaho | 83814 | — |
| Site 1015 | Springfield | Illinois | 62769 | — |
| Site 1023 | Jeffersonville | Indiana | 47130 | — |
| Site 1014 | West Des Moines | Iowa | 50266 | — |
| Site 1012 | Shreveport | Louisiana | 71106 | — |
| Site 1002 | Royal Oak | Michigan | 48072 | — |
| Site 1011 | Albuquerque | New Mexico | 87109 | — |
| Site 1009 | Lake Success | New York | 11042 | — |
| Site 1021 | Charlotte | North Carolina | 28207 | — |
| Site 1008 | Raleigh | North Carolina | 27612 | — |
| Site 1019 | Wilmington | North Carolina | 28401 | — |
| Site 1001 | Cleveland | Ohio | 44195 | — |
| Site 1017 | Oklahoma City | Oklahoma | 73120 | — |
| Site 1007 | Philadelphia | Pennsylvania | 19140 | — |
| Site 1022 | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03500159, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 9, 2019 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03500159 live on ClinicalTrials.gov.